Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155278 | 0.94 | — | — | |
| SCHEMBL8058198 | 0.94 | MEN1 (0.75) | MEN1KMT2ACA5ACA5BTSHR | |
| Silver SCHEMBL961 | 0.94 | — | — | |
| Silver SCHEMBL1326350 | 0.94 | MEN1 (0.75) | MEN1KMT2ACA5ACA5BTSHR | |
| Water SCHEMBL7567964 | 0.88 | MEN1 (0.67) | MEN1KMT2ACA5ACA5BTSHR | |
| SCHEMBL9443297 | 0.88 | MEN1 (0.67) | MEN1KMT2ACA5ACA5BTSHR | |
| Silver SCHEMBL2253632 | 0.88 | MEN1 (0.67) | MEN1KMT2ACA5ACA5BTSHR | |
| Silver SCHEMBL4475369 | 0.88 | — | — | |
| SCHEMBL15814439 | 0.88 | MEN1 (0.67) | MEN1KMT2ACA5ACA5BTSHR | |
| Silver SCHEMBL11862482 | 0.88 | MEN1 (0.67) | MEN1KMT2ACA5ACA5BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107815544-A | Noble metal is obtained using synthesized environmental protection method processing industrial solid castoff | 江西新金叶实业有限公司 | 2018-03-20 | — | — | CN | claimed |
| CN-118616727-A | Micron-sized silver powder prepared by adopting nitrogen-free dispersing agent and preparation method thereof | 深圳市哈深智材科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-115449012-A | High-adsorption resin polymerized by standing at normal temperature and preparation method and application thereof | 岭南师范学院 | 2022-12-09 | — | — | CN | disclosed |
| CN-214598667-U | Silver nitrate blending device for lead removal and purification of silver nitrate | 夏县运力化工有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-108347890-A | The gene transgression of yield QTL in cucumber plant | 纽海姆有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-2270018-A1 | Antitumoral analogs | Pharma Mar, S.A. (ES) | 2011-01-05 | — | — | EP | disclosed |
| US-7763615-B2 | Ecteinascidin analogs for use as antitumour agents | PHARMA MAR, S.A. (ES) | 2010-07-27 | — | — | US | disclosed |
| EP-1414828-B9 | ANTITUMORAL ANALOGS | PHARMA MAR SA (ES) | 2008-02-20 | — | — | EP | disclosed |
| EP-1414828-B1 | ANTITUMORAL ANALOGS | PHARMA MAR SA (ES) | 2007-10-03 | — | — | EP | disclosed |
| EP-1806349-A1 | ANTITUMORAL ANALOGS | Pharma Mar, S.A. (ES) | 2007-07-11 | — | — | EP | disclosed |
| US-20060128711-A1 | derivatives of ecteinascidins, particularly ecteinascidin 736, used for the treatment of lung, colon, kidney, prostate, cervical, ovarian, breast or pancreatic cancer, leukaemia or melanoma in mammals; reduced systemic toxicity and improved pharmacokinetics | PHARMA MAR, S.A. (ES) | 2006-06-15 | — | — | US | disclosed |
| EP-1414828-A1 | ANTITUMORAL ANALOGS | PHARMA MAR, S.A. (ES) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014127-A1 | ANTITUMORAL ANALOGS | PHARMA MAR, S.A. (ES) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128711-A1 | derivatives of ecteinascidins, particularly ecteinascidin 736, used for the treatment of lung, colon, kidney, prostate, cervical, ovarian, breast or pancreatic cancer, leukaemia or melanoma in mammals; reduced systemic toxicity and improved pharmacokinetics | TEK, OGFR, OGFRL1 | MEN1 1405/4885KMT2A 4755/4885CA5A 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.